Dxd

• Description :

  Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .

• Product Name Alternative :

  Exatecan derivative for ADC

• UNSPSC :

  12352203

• Hazard Statement :

  H301

• Target :

  ADC Payload; Topoisomerase

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Dxd.html

• Purity :

  99.43

• Solubility :

  DMSO : 40 mg/mL (ultrasonic)

• Smiles :

  O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5NC(CO)=O)C(C)=C(F)C=C6N=C4C3=C2)=O

• Molecular Formula :

  C26H24FN3O6

• Molecular Weight :

  493.48

• Precautions :

  H301

• References & Citations :

  [1]Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22 (20) :5097-5108.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  ADC Related

• Clinical Information :

  Phase 2

• Isoform :

  Camptothecins; Topo I

• CAS Number :

  [1599440-33-1]